Basket Study for Oligo-metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2034

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.

Trial Locations (1)

Unknown

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER